Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 1:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Not listed Not applicable Interventional Accepts healthy volunteers

Perceptual Deficits in Schizophrenia

NCT02337439
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Sensory Information Processing Training, Active Control Training
Behavioral
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Schizophrenia
Interventions
Placebo, RO4917838, Standard Antipsychotic Therapy
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Orangeburg, New York
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Cognitive Function Assessments
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 30 Years
Enrollment
139 participants
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia

NCT07788755
Conditions
Schizophrenia, Schizoaffective Disorder, Cognitive Impairment, Visual Impairment
Interventions
Perceptual Discrimination Training, Cognitive Control Training
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 79 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Cognitive Dysfunction, Schizophrenia
Interventions
KYN-5356, placebo
Drug
Lead sponsor
Kynexis B.V.
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Conditions
Schizophrenia
Interventions
D-cycloserine, Placebo, Cognitive Remediation
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia

NCT00423943
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
modafinil, Placebos
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 54 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Schizophrenia
Interventions
Galantamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Schizophrenia Disorders
Interventions
Placebo (single and multiple doses), AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Glendale, California • Willingboro, New Jersey
Conditions
Schizophrenia
Interventions
Atomoxetine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Catonsville, Maryland
Completed Phase 4 Interventional Results available

Varenicline Adjunctive Treatment in Schizophrenia

NCT00492349
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland
Conditions
Schizophrenia
Interventions
PF-04958242, Ketamine, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
21 Years to 45 Years · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Conditions
Schizophrenia, Cognition, Psychosis
Interventions
Curcumin, Placebo
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Schizophrenia, Dementia
Interventions
Huperzine A
Drug
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
19 Years to 59 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Cognitive Deficits in Schizophrenia
Interventions
ABT-288 Low Dose, Placebo, ABT-288 High Dose
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
20 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Anaheim, California • Garden Grove, California • National City, California + 20 more
Conditions
Schizophrenia
Interventions
Org 24448, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Los Angeles, California • Catonsville, Maryland • Boston, Massachusetts + 4 more
Conditions
Schizophrenia
Interventions
AVE1625, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
873 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Schizophrenia, Cognitive Impairment
Interventions
ALTO-101, ALTO-101 Transdermal Delivery System, Placebo, Placebo Transdermal Delivery System
Drug · Device
Lead sponsor
Alto Neuroscience
Industry
Eligibility
21 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Garden Grove, California • Los Angeles, California • Orange, California + 9 more
Conditions
Schizophrenia
Interventions
MK-0777, placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Catonsville, Maryland • Boston, Massachusetts + 4 more
Conditions
Schizophrenia
Interventions
PF-3463275, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Glendale, California • Willingboro, New Jersey
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
38
States / cities
Tucson, Arizona • Anaheim, California • Bellflower, California + 35 more
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Galantamine ER, Memantine XR
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
Interventions
RL-007 (Inidascamine), Placebo
Drug
Lead sponsor
Recognify Life Sciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Culver City, California • Garden Grove, California • Lafayette, California + 17 more
Conditions
Schizophrenia
Interventions
Plasticity-based Cognitive Training, Non-plasticity-based Training
Other
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Palo Alto, California • San Francisco, California